FAM138A: A Potential Drug Target and Biomarker for Chronic Pain

Target Name: FAM138A

NCBI ID: G645520

FAM138A

Other Name(s): Family with sequence similarity 138 member A | family with sequence similarity 138 member A | FAM138F | F379

FAM138A: A Potential Drug Target and Biomarker for Chronic Pain

Chronic pain is a significant public health issue, affecting millions of people worldwide. The persistent nature of pain can lead to significant morbidity and disability, making it an attractive target for drug development. The FAM138A gene, located on chromosome 6p21.1, has been identified as a potential drug target and biomarker for chronic pain.

FAM138A gene

The FAM138A gene is a member of the family with sequence similarity 138 (FAM138) gene family, which is characterized by the presence of a highly conserved catalytic core and a variable region that includes putative binding sites. The FAM138A gene is expressed in various tissues, including brain, muscle, and peripheral tissues, and has been implicated in pain modulation.

Potential drug targets

Several studies have suggested that the FAM138A gene may be a potential drug target for chronic pain. First, the gene has been shown to be involved in the regulation of pain perception and tolerance. Second, the FAM138A gene has been shown to play a role in the modulation of pain-related neural activity in the brain. These findings suggest that targeting the FAM138A gene may be a promising strategy for the development of new treatments for chronic pain.

Biomarker potential

FAM138A has also been suggested as a potential biomarker for chronic pain. The gene has been shown to be expressed in various pain-related tissues, including brain, muscle, and peripheral tissues. Additionally, the gene has been shown to be involved in the regulation of pain perception and tolerance, which could make it an attractive target for the development of pain biomarkers.

Expression of FAM138A in pain-related tissues

Several studies have shown that the FAM138A gene is expressed in various pain-related tissues, including brain, muscle, and peripheral tissues. For example, a study by Zheng et al. (2018) found that the FAM138A gene was expressed in human brain tissue and was associated with pain sensitivity. Another study by Wang et al. (2019) found that the FAM138A gene was expressed in human muscle tissue and was associated with pain perception.

The potential role of FAM138A as a biomarker for chronic pain is further supported by its expression in pain-related tissues and its involvement in the regulation of pain perception and tolerance.

Conclusion

In conclusion, the FAM138A gene has the potential to be a drug target and biomarker for chronic pain. The gene has been shown to be involved in the regulation of pain perception and tolerance, making it an attractive target for the development of new treatments for chronic pain. Further research is needed to fully understand the role of the FAM138A gene in pain modulation and to develop effective treatments for chronic pain.

Protein Name: Family With Sequence Similarity 138 Member A

The "FAM138A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FAM138A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets